Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy.
immunotherapy
metabolic reprogramming
oncolytic virus
tumor microenvironment
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 11 2022
15 11 2022
Historique:
revised:
11
05
2022
received:
01
03
2022
accepted:
16
05
2022
pubmed:
29
5
2022
medline:
28
9
2022
entrez:
28
5
2022
Statut:
ppublish
Résumé
Oncolytic viruses (OVs) represent a class of cancer immunotherapies that rely on hijacking the host cell factory for replicative oncolysis and eliciting immune responses for tumor clearance. An increasing evidence suggests that the metabolic state of tumor cells and immune cells is a putative determinant of the efficacy of cancer immunotherapy. However, how therapeutic intervention with OVs affects metabolic fluxes within the tumor microenvironment (TME) remains poorly understood. Herein, we review the complexities of metabolic reprogramming involving the effects of viruses and their consequences on tumor cells and immune cells. We highlight the inherent drawback of oncolytic virotherapy, namely that treatment with OVs inevitably further exacerbates the depletion of nutrients and the accumulation of metabolic wastes in the TME, leading to a metabolic barrier to antitumor immune responses. We also describe targeted metabolic strategies that can be used to unlock the therapeutic potential of OVs.
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1654-1662Informations de copyright
© 2022 UICC.
Références
Zuo S, Wei M, He B, et al. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). EBioMedicine. 2021;64:103240.
Zhang Y, Zhang H, Wei M, et al. Recombinant adenovirus expressing a soluble fusion protein PD-1/CD137L subverts the suppression of CD8(+) T cells in HCC. Mol Ther. 2019;27:1906-1918.
Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109-1119.e10.
Samson A, Scott KJ, Taggart D, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 2018;10(422):eaam7577.
Zuo S, Wei M, Xu T, et al. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. J Immunother Cancer. 2021;9:e002843.
Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020;16:2389-2402.
Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43:435-449.
O'Sullivan D, Sanin DE, Pearce EJ, Pearce EL. Metabolic interventions in the immune response to cancer. Nat Rev Immunol. 2019;19:324-335.
DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21:785-797.
Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15:651-659.
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907-1918.
Ilkow CS, Marguerie M, Batenchuk C, et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med. 2015;21:530-536.
Stanford MM, Barrett JW, Nazarian SH, Werden S, McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J Virol. 2007;81:1251-1260.
Ilkow CS, Swift SL, Bell JC, Diallo JS. From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. PLoS Pathog. 2014;10:e1003836.
Fendt SM, Frezza C, Erez A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 2020;10:1797-1807.
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27-47.
Magalhaes I, Yogev O, Mattsson J, Schurich A. The metabolic profile of tumor and virally infected cells shapes their microenvironment counteracting T cell immunity. Front Immunol. 2019;10:2309.
Prince A, Wong Fok Lung T. Consequences of metabolic interactions during Staphylococcus aureus infection. Toxins (Basel). 2020;12:12.
Yin Y, Dang W, Zhou X, et al. PI3K-Akt-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. Virulence. 2018;9:83-98.
Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2017;36:2191-2201.
Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177-185.
Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705-713.
Lim S, Phillips JB, Madeira da Silva L, et al. Interplay between immune checkpoint proteins and cellular metabolism. Cancer Res. 2017;77:1245-1249.
Passalacqua KD, Lu J, Goodfellow I, et al. Glycolysis is an intrinsic factor for optimal replication of a norovirus. MBio. 2019;10(2):e02175-18.
Eagle H. The minimum vitamin requirements of the L and HeLa cells in tissue culture, the production of specific vitamin deficiencies, and their cure. J Exp Med. 1955;102:595-600.
Bowles TL, Kim R, Galante J, et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer. 2008;123:1950-1955.
Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105:18782-18787.
Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136:521-534.
Boodhoo N, Kamble N, Sharif S, Behboudi S. Glutaminolysis and glycolysis are essential for optimal replication of Marek's disease virus. J Virol. 2020;94(4):e01680-19.
Dyer A, Schoeps B, Frost S, et al. Antagonism of glycolysis and reductive carboxylation of glutamine potentiates activity of oncolytic adenoviruses in cancer cells. Cancer Res. 2019;79:331-345.
Dai L, Lin Z, Jiang W, Flemington EK, Qin Z. Lipids, lipid metabolism and Kaposi's sarcoma-associated herpesvirus pathogenesis. Virol Sin. 2017;32:369-375.
Hofmann S, Krajewski M, Scherer C, et al. Complex lipid metabolic remodeling is required for efficient hepatitis C virus replication. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:1041-1056.
Chakraborty S, ValiyaVeettil M, Sadagopan S, Paudel N, Chandran B. c-Cbl-mediated selective virus-receptor translocations into lipid rafts regulate productive Kaposi's sarcoma-associated herpesvirus infection in endothelial cells. J Virol. 2011;85:12410-12430.
Raghu H, Sharma-Walia N, Veettil MV, et al. Lipid rafts of primary endothelial cells are essential for Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-induced phosphatidylinositol 3-kinase and RhoA-GTPases critical for microtubule dynamics and nuclear delivery of viral DNA but dispensable for binding and entry. J Virol. 2007;81:7941-7959.
Bandara LR, La Thangue NB. Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature. 1991;351:494-497.
Kim M, Williamson CT, Prudhomme J, et al. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene. 2010;29:3990-3996.
Vijayalingam S, Subramanian T, Ryerse J, Varvares M, Chinnadurai G. Down-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5. Virology. 2009;392:62-72.
Maroun J, Munoz-Alia M, Ammayappan A, Schulze A, Peng KW, Russell S. Designing and building oncolytic viruses. Future Virol. 2017;12:193-213.
Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999;5:881-887.
Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A. 2006;103:12873-12878.
Jia R, Chen Y, Jia C, Hu B, Du Y. Suppression of innate immune signaling molecule, MAVS, reduces radiation-induced bystander effect. Int J Radiat Biol. 2021;97:102-110.
Della Corte CM, Sen T, Gay CM, et al. STING pathway expression identifies NSCLC with an immune-responsive phenotype. J Thorac Oncol. 2020;15:777-791.
Koshiba T. Mitochondrial-mediated antiviral immunity. Biochim Biophys Acta. 2013;1833:225-232.
Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263-275.
Burke JD, Platanias LC, Fish EN. Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3. J Virol. 2014;88:3485-3495.
Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82:103-126.
Harmon C, Robinson MW, Hand F, et al. Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis. Cancer Immunol Res. 2019;7:335-346.
Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559-563.
Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812-3819.
Rivadeneira DB, DePeaux K, Wang Y, et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity. 2019;51:548-560.e4.
Riera-Domingo C, Audige A, Granja S, et al. Immunity, hypoxia, and metabolism-the menage a trois of cancer: implications for immunotherapy. Physiol Rev. 2020;100:1-102.
Uehara T, Eikawa S, Nishida M, et al. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects. Int Immunol. 2019;31:187-198.
Terren I, Orrantia A, Vitalle J, Zenarruzabeitia O, Borrego F. NK cell metabolism and tumor microenvironment. Front Immunol. 2019;10:2278.
Geiger R, Rieckmann JC, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167:829-842.e13.
Mussai F, De Santo C, Abu-Dayyeh I, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122:749-758.
Goossens P, Rodriguez-Vita J, Etzerodt A, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29:1376-1389.e4.
Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24:657-671.
Giovanelli P, Sandoval TA, Cubillos-Ruiz JR. Dendritic cell metabolism and function in tumors. Trends Immunol. 2019;40:699-718.
Moreno-Altamirano MMB, Kolstoe SE, Sanchez-Garcia FJ. Virus control of cell metabolism for replication and evasion of host immune responses. Front Cell Infect Microbiol. 2019;9:95.
Thaker SK, Ch'ng J, Christofk HR. Viral hijacking of cellular metabolism. BMC Biol. 2019;17:59.
Codo AC, Davanzo GG, Monteiro LB, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis. Cell Metab. 2020;32:437-446.e5.
Kennedy BE, Murphy JP, Clements DR, et al. Inhibition of pyruvate dehydrogenase kinase enhances the antitumor efficacy of oncolytic reovirus. Cancer Res. 2019;79:3824-3836.
Meng G, Li B, Chen A, et al. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma. Br J Cancer. 2020;122:111-120.
Gong Y, Tang N, Liu P, et al. Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells. Autophagy. 2021;1-19. doi:10.1080/15548627.2021.1990515
Li C, Meng G, Su L, et al. Dichloroacetate blocks aerobic glycolytic adaptation to attenuated measles virus and promotes viral replication leading to enhanced oncolysis in glioblastoma. Oncotarget. 2015;6:1544-1555.
Lévy PL, Duponchel S, Eischeid H, et al. Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology. 2017;65:789-803.
Dyer A, Schoeps B, Frost S, et al. Antagonism of glycolysis and reductive carboxylation of glutamine potentiates activity of oncolytic adenoviruses in cancer cells. Cancer Res. 2019;79:331-345.
Delafiori J, Lima EO, Dabaja MZ, et al. Molecular signatures associated with prostate cancer cell line (PC-3) exposure to inactivated Zika virus. Sci Rep. 2019;9:15351.
Fedosyuk S, Bezerra GA, Radakovics K, et al. Vaccinia virus immunomodulator A46: a lipid and protein-binding scaffold for sequestering host TIR-domain proteins. PLoS Pathog. 2016;12:e1006079.
Thai M, Graham NA, Braas D, et al. Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab. 2014;19:694-701.
Grady SL, Purdy JG, Rabinowitz JD, Shenk T. Argininosuccinate synthetase 1 depletion produces a metabolic state conducive to herpes simplex virus 1 infection. Proc Natl Acad Sci U S A. 2013;110:E5006-E5015.
Mazzon M, Peters NE, Loenarz C, et al. A mechanism for induction of a hypoxic response by vaccinia virus. Proc Natl Acad Sci U S A. 2013;110:12444-12449.
Sharma-Walia N, Chandran K, Patel K, Veettil MV, Marginean A. The Kaposi's sarcoma-associated herpesvirus (KSHV)-induced 5-lipoxygenase-leukotriene B4 cascade plays key roles in KSHV latency, monocyte recruitment, and lipogenesis. J Virol. 2014;88:2131-2156.
Serquina AKP, Kambach DM, Sarker O, Ziegelbauer JM. Viral microRNAs repress the cholesterol pathway, and 25-hydroxycholesterol inhibits infection. MBio. 2017;8(4):e00576-17.
Al-Khami AA, Rodriguez PC, Ochoa AC. Energy metabolic pathways control the fate and function of myeloid immune cells. J Leukoc Biol. 2017;102:369-380.
Zhang L, Romero P. Metabolic control of CD8(+) T cell fate decisions and antitumor immunity. Trends Mol Med. 2018;24:30-48.
Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48:812-830.e14.
Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36-50.
Su P, Wang Q, Bi E, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res. 2020;80:1438-1450.
Netea-Maier RT, Smit JWA, Netea MG. Metabolic changes in tumor cells and tumor-associated macrophages: a mutual relationship. Cancer Lett. 2018;413:102-109.
Gauthier T, Chen W. Modulation of macrophage immunometabolism: a new approach to fight infections. Front Immunol. 2022;13:780839.
Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120:16-25.
Chang CH, Curtis JD, Maggi LB Jr, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153:1239-1251.
Finlay DK, Rosenzweig E, Sinclair LV, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012;209:2441-2453.
Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol. 2020;20:55-70.
Yu YR, Ho PC. Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting. Clin Exp Immunol. 2019;197:153-160.
Johnson MO, Wolf MM, Madden MZ, et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell. 2018;175:1780-1795.e19.
Bengsch B, Johnson AL, Kurachi M, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity. 2016;45:358-373.
Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169:570-586.
Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. Nature. 2014;511:167-176.
Angelin A, Gil-de-Gomez L, Dahiya S, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 2017;25:1282-1293.e7.
Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68:916-927.
Lim SA, Wei J, Nguyen TM, et al. Lipid signalling enforces functional specialization of Treg cells in tumours. Nature. 2021;591:306-311.
Al-Shammari AM, Abdullah AH, Allami ZM, Yaseen NY. 2-Deoxyglucose and Newcastle disease virus synergize to kill breast cancer cells by inhibition of glycolysis pathway through glyceraldehyde3-phosphate downregulation. Front Mol Biosci. 2019;6:90.
Wang Y, Li JR, Sun MX, et al. Triggering unfolded protein response by 2-deoxy-d-glucose inhibits porcine epidemic diarrhea virus propagation. Antiviral Res. 2014;106:33-41.
Ludwig H, Becht H, Rott R. Inhibition of herpes virus-induced cell fusion by concanavalin A, antisera, and 2-deoxy-d-glucose. J Virol. 1974;14:307-314.
Zhou Y, Wen F, Zhang P, Tang R, Li Q. Vesicular stomatitis virus is a potent agent for the treatment of malignant ascites. Oncol Rep. 2016;35:1573-1581.
Xiao L, Li X, Niu N, Qian J, Xie G, Wang Y. Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Mol Cell Biochem. 2010;340:31-40.
Levy PL, Duponchel S, Eischeid H, et al. Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology. 2017;65:789-803.
Sumbria D, Berber E, Miller L, Rouse BT. Modulating glutamine metabolism to control viral immuno-inflammatory lesions. Cell Immunol. 2021;370:104450.
Leone RD, Zhao L, Englert JM, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013-1021.
Qiao H, Chen X, Wang Q, et al. Tumor localization of oncolytic adenovirus assisted by pH-degradable microgels with JQ1-mediated boosting replication and PD-L1 suppression for enhanced cancer therapy. Biomater Sci. 2020;8:2472-2480.
Rodrigues AF, Formas-Oliveira AS, Bandeira VS, Alves PM, Hu WS, Coroadinha AS. Metabolic pathways recruited in the production of a recombinant enveloped virus: mining targets for process and cell engineering. Metab Eng. 2013;20:131-145.
Silberhumer GR, Zakian K, Malhotra S, et al. Relationship between 31P metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts. Br J Surg. 2009;96:809-816.
Rodrigues AF, Carrondo MJ, Alves PM, Coroadinha AS. Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells. Trends Biotechnol. 2014;32:602-607.